EGFR tyrosine kinase inhibitors in squamous cell lung cancer

Fred R. Hirsch; Roy S. Herbst; David R. Gandara

doi:10.1016/S1470-2045(15)00126-6

EGFR tyrosine kinase inhibitors in squamous cell lung cancer

Fred R. Hirsch
, Roy S. Herbst
, David R. Gandara

Research output: Contribution to journal › Comment/debate

9 Scopus citations

Original language	English
Pages (from-to)	872-873
Number of pages	2
Journal	The Lancet Oncology
Volume	16
Issue number	8
DOIs	https://doi.org/10.1016/S1470-2045(15)00126-6
State	Published - 1 Aug 2015
Externally published	Yes

Access to Document

10.1016/S1470-2045(15)00126-6

Cite this

@article{6d5098099c51447f854e1e9575f1d291,

title = "EGFR tyrosine kinase inhibitors in squamous cell lung cancer",

author = "Hirsch, \{Fred R.\} and Herbst, \{Roy S.\} and Gandara, \{David R.\}",

note = "Funding Information: FRH has served on advisory boards for Lilly/Imclone, Genentech/Roche, AstraZeneca, Pfizer, Novartis, and Bristol-Myers Squibb. RSH has consulted for Boehringer Ingelheim. DRG has received grants from Genentech, and has consulted for Genentech and Boehringer Ingelheim.",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/S1470-2045(15)00126-6",

language = "English",

volume = "16",

pages = "872--873",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - EGFR tyrosine kinase inhibitors in squamous cell lung cancer

AU - Hirsch, Fred R.

AU - Herbst, Roy S.

AU - Gandara, David R.

N1 - Funding Information: FRH has served on advisory boards for Lilly/Imclone, Genentech/Roche, AstraZeneca, Pfizer, Novartis, and Bristol-Myers Squibb. RSH has consulted for Boehringer Ingelheim. DRG has received grants from Genentech, and has consulted for Genentech and Boehringer Ingelheim.

PY - 2015/8/1

Y1 - 2015/8/1

UR - https://www.scopus.com/pages/publications/84938203170

U2 - 10.1016/S1470-2045(15)00126-6

DO - 10.1016/S1470-2045(15)00126-6

M3 - Comment/debate

C2 - 26156654

AN - SCOPUS:84938203170

SN - 1470-2045

VL - 16

SP - 872

EP - 873

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 8

ER -